Cargando…
COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes
Adenoviral-based vaccines such as ChadoX1 CoV-19 (AstraZeneca) and Ad26.COV2.S (J&J) were developed to prevent infection and reduce hospitalization or death in Coronavirus Disease 2019 (COVID-19) patients. Although these vaccines passed safety and efficacy trials with excellent neutralizing capa...
Autores principales: | Allas, Gewil Daniella Olipas, Arizala, Joekeem Del Rosario, Manalo, Rafael Vincent Mercado |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778187/ https://www.ncbi.nlm.nih.gov/pubmed/36547234 http://dx.doi.org/10.3390/hematolrep14040050 |
Ejemplares similares
-
Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family
por: Noyé, Mickaël, et al.
Publicado: (2022) -
Vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Warkentin, Theodore E.
Publicado: (2022) -
Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
por: Dix, Caroline, et al.
Publicado: (2022) -
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Greinacher, Andreas, et al.
Publicado: (2022) -
Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Gabarin, Nadia, et al.
Publicado: (2022)